Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Safety and Feasibility of Central Intravenous Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Pulmonary Arterial Hypertension ALPHA Trial

NCT03145298 is registered in ClinicalTrials.gov with Cedars-Sinai Medical Center as lead sponsor.

NCT NCT03145298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03145298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Safety and Feasibility of Central Intravenous Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Pulmonary Arterial Hypertension ALPHA Trial
Lead sponsor
Cedars-Sinai Medical Center
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2017
Completion date
March 31, 2023
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension (pah)